Study on the effects of an OCT2/MATE1 substrate (metformin) and inhibitor (cimetidine) on the exposure of trifluridine/tipiracil (Lonsurf) in patients with metastatic colorectal cancer (mCRC).
Ontology highlight
ABSTRACT: Interventions: Patients treated with Lonsurf will be treated with metformin and cimetidine for 7 and 5 consecutive days respectively.
Primary outcome(s): 1. To determine the possible drug interaction between Lonsurf and metformin on Lonsurf plasma pharmacokinetics (AUC) in patients with metastatic colorectal cancer.
2. To determine the possible interaction between Lonsurf and cimetidine on Lonsurf plasma pharmacokinetics (AUC) in patients with metastatic colorectal cancer.
Study Design: N/A: single arm study, Open (masking not used), Active, Crossover
DISEASE(S): Metastatic Colorectal Cancer With An Indication For Lonsurf Treatment
PROVIDER: 2442600 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA